U.S. market Open. Closes in 2 hours 10 minutes

LXEO | Lexeo Therapeutics, Inc. Common Stock Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-31
RevenueN/A654.00K1.66M518.48K
Cost of Revenue1.84M1.15M13.40KN/A
Gross Profit-1.84M-491.00K1.64M518.48K
Operating Expenses66.67M61.16M52.29M5.11M
Selling, General & Admin13.54M12.00M7.17M787.50K
Research & Development53.13M49.16M45.12M4.32M
Other Operating ExpensesN/A-2.00K-155.004.24K
Operating Income-68.51M-60.51M-50.64M-4.59M
Other Expenses / Income2.12M-2.00K-155.00-417.85K
Before Tax Income-66.39M-59.28M-50.62M-5.15M
Income Tax Expenses-1.0089.00K-155.00147.15K
Net Income-66.39M-59.28M-50.62M-5.15M
Interest Expenses205.00K91.00KN/A147.15K
Basic Shares Outstanding26.65M24.67M24.67M24.67M
Diluted Shares Outstanding26.65M24.67M24.67M24.67M
EBITDA-66.67M-58.04M-50.61M-4.58M
EBITDA Margin0.00%-8,874.77%-3,054.25%-884.04%
EBIT-66.19M-59.10M-50.62M-4.86M
EBIT Margin0.00%-9,036.24%-3,055.05%-937.07%
Financial Year End2023-12-312022-12-312021-12-312020-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙